A Phase 1b Study to Characterize the Safety and Tolerability of TEV-53408 in Adults with Celiac Disease
Phase 1
Active, not recruiting
- Conditions
- Celiac disease
- Registration Number
- 2022-502817-27-00
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing, recruitment ended
- Sex
- Not specified
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Clinical Research Services Turku Oy
🇫🇮Turku, Finland
Pirkanmaan hyvinvointialue
🇫🇮Tampere, Finland
Clinical Research Services Turku Oy🇫🇮Turku, FinlandMax KiugelSite contact+358407424607max.kiugel@crst.fi